Blood Advances
Издатель: Elsevier · ISSN 2473-9529 · 89 статей
- Comprehensive genetic characterization of adult BCR::ABL1-negative B-ALL by optical genome mapping and targeted NGS
- Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma
- Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs
- Second-line CD19 CAR T vs platinum salvage and autologous stem cell transplant for primary mediastinal B-cell lymphoma
- Assessment of the IPSS-M in chronic myelomonocytic leukemia
- The NLRC4 inflammasome drives myelodysplastic syndrome by linking epigenetic reprogramming and innate immune signaling
- Jagunal homolog 1 safeguards neutrophil immune function by preserving protein sialylation during differentiation
- Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa
- Genetic and laboratory predictors of bleeding severity in FVII deficiency: insights from the PRO-RBDD and EN-RBD databases
- Activated platelets protect factor VIIIa from degradation by activated protein C and from subunit dissociation
- Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion-dependent thalassemia in LMICs
- Clonal hematopoiesis in autoimmune hemolytic anemia
- Adaptive NK-cell dominance linked to HLH susceptibility in VEXAS syndrome
- The loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma
- Interpreting cord blood transplant outcomes in BMT CTN 1702
- Iron deficiency: cost-effectiveness and global applicability
- Umbilical cord blood donor outcomes in BMTCTN1702
- Fracturing ferric carboxymaltose from the iron pharmacopeia
- Sorror ML, Saber W, Logan B, et al. Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704. Blood Adv. 2025;9(13):3268-3280.
- Hu B, Reagan PM, Sehn LH, et al. Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Adv. 2025;9(10):2489-2499.
- Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma:
- Idiopathic Multicentric Castleman Disease Unresponsive to One IL-6 Inhibitor May Respond to Another IL-6 Inhibitor
- Active Surveillance of JAK2V617F Clonal Hematopoiesis Toward Myeloproliferative Neoplasms
- Racial and Ethnic Differences in the Incidence of Langerhans Cell Histiocytosis Across the Age Spectrum
- CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study
- Interpreting recurrence estimates in thrombophilia
- Characterizing clinical heterogeneity by whole-genome sequencing of 591 patients with Hemoglobin H disease
- Cytoreduction for MPN-associated splanchnic vein thrombosis
- Blinatumomab for pediatric B-ALL in LMICs: promise or peril?
- Salvage at molecular relapse: many paths, few signposts